litlas
Log inCreate account

J. Randolph Hecht

Active 1998–2026

79
Papers
20,839
Citations
53
h-index
70
i10-index

Citations

Citations per year for J. Randolph Hecht1985: 1 citations1990: 1 citations1999: 1 citations2000: 1 citations2001: 4 citations2002: 3 citations2003: 12 citations2004: 30 citations2005: 59 citations2006: 96 citations2007: 139 citations2008: 104 citations2009: 155 citations2010: 201 citations2011: 166 citations2012: 184 citations2013: 206 citations2014: 206 citations2015: 220 citations2016: 211 citations2017: 207 citations2018: 169 citations2019: 513 citations2020: 461 citations2021: 500 citations2022: 451 citations2023: 317 citations2024: 654 citations2025: 375 citations2026: 16 citations1986–1989: no citations, so these years are not shown1991–1998: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,142 citing papers, 26.5% of this breakdownChina: 952 citing papers, 11.8% of this breakdownItaly: 518 citing papers, 6.4% of this breakdownUnited Kingdom: 487 citing papers, 6% of this breakdownGermany: 455 citing papers, 5.6% of this breakdownFrance: 373 citing papers, 4.6% of this breakdownJapan: 366 citing papers, 4.5% of this breakdownSpain: 310 citing papers, 3.9% of this breakdownNetherlands: 243 citing papers, 3% of this breakdownCanada: 211 citing papers, 2.6% of this breakdownAustralia: 198 citing papers, 2.5% of this breakdownSouth Korea: 181 citing papers, 2.3% of this breakdown
0%26.5%Other 20.3%

Institutions

Fields

  • Medicine65.7%
  • Biochemistry, Genetics and Molecular Biology26.8%
  • Immunology and Microbiology3%
  • Materials Science0.8%
  • Computer Science0.7%
  • Engineering0.7%
  • Other2.3%

Topics

  • Colorectal Cancer Treatments and Studies7.8%
  • Cancer Genomics and Diagnostics6.3%
  • Pancreatic and Hepatic Oncology Research5.4%
  • Colorectal Cancer Surgical Treatments3.2%
  • Lung Cancer Treatments and Mutations3.1%
  • Cancer Immunotherapy and Biomarkers2.9%
  • Other71.3%

Coauthors

All papers

Open in search
  1. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

    Authors: Al B. Benson, Alan P. Venook, Mahmoud M. Al-Hawary, Mustafa A. Arain, Yi‐Jen Chen, Kristen K. Ciombor, Stacey A. Cohen, Harry S. Cooper, Dustin A. Deming, Linda M. Farkas, Ignacio Garrido‐Laguna, Jean L. Grem, Andrew J. Gunn, J. Randolph Hecht, Sarah E. Hoffe, Joleen M. Hubbard, Steven R. Hunt, Kimberly L. Johung, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey A. Meyerhardt, Eric D. Miller, Mary F. Mulcahy, Steven Nurkin, Michael J. Overman, Aparna R. Parikh, Hitendra Patel, Katrina S. Pedersen, Leonard B. Saltz, Charles Schneider, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky‐Himelfarb, Christopher G. Willett, Kristina M. Gregory, Lisa A. Gurski - Journal of the National Comprehensive Cancer Network 2021 cited by 1,748

  2. Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

    Authors: Al B. Benson, Alan P. Venook, Mahmoud M. Al-Hawary, Nilofer Azad, Yi‐Jen Chen, Kristen K. Ciombor, Stacey A. Cohen, Harry S. Cooper, Dustin A. Deming, Ignacio Garrido‐Laguna, Jean L. Grem, Andrew J. Gunn, J. Randolph Hecht, Sarah E. Hoffe, Joleen M. Hubbard, Steven R. Hunt, William R. Jeck, Kimberly L. Johung, Natalie Kirilcuk, Smitha Krishnamurthi, Jennifer K. Maratt, Wells A. Messersmith, Jeffrey A. Meyerhardt, Eric D. Miller, Mary F. Mulcahy, Steven Nurkin, Michael J. Overman, Aparna Parikh, Hitendra Patel, Katrina S. Pedersen, Leonard B. Saltz, Charles Schneider, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Eden Stotsky‐Himelfarb, Anna Tavakkoli, Christopher G. Willett, Kristina M. Gregory, Lisa A. Gurski - Journal of the National Comprehensive Cancer Network 2022 cited by 819

  3. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

    Authors: Malcolm J. Moore, David Goldstein, John Hamm, Arié Figer, J. Randolph Hecht, Steven Gallinger, H. Au, P. Murawa, David Walde, Robert A. Wolff, Daniel de Castro, Robert Lim, Keyue Ding, Gary M. Clark, Theodora Voskoglou-Nomikos, Mieke Ptasynski, Wendy R. Parulekar - Journal of Clinical Oncology 2007 cited by 3,859

  4. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

    Authors: Luis A. Díaz, Richard T. Williams, Jian Wu, Isaac Kinde, J. Randolph Hecht, Jordan Berlin, Benjamin Allen, Ivana Božić, Johannes G. Reiter, Martin A. Nowak, Kenneth W. Kinzler, Kelly S. Oliner, Bert Vogelstein - Nature 2012 cited by 1,748

  5. A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results

    Authors: Amy Rappaport, Chrisann Kyi, Monica Lane, Meghan G. Hart, Melissa L. Johnson, Brian S. Henick, Chih‐Yi Liao, Amit Mahipal, Ardaman Shergill, Alexander I. Spira, Jonathan W. Goldman, Ciaran D. Scallan, Desiree Schenk, Christine D. Palmer, Matthew J. Davis, Sonia Kounlavouth, Lindsey Kemp, Aaron Yang, Y. Li, Molly Likes, Annie Shen, Gregory R. Boucher, Milana Egorova, Robert L. Veres, J. Aaron Espinosa, Jason R. Jaroslavsky, Lauren D. Kraemer Tardif, Lindsey Acrebuche, Christopher Puccia, Leiliane Sousa, Rita Zhou, Kyounghwa Bae, J. Randolph Hecht, David P. Carbone, Benny Johnson, Andrew M. Allen, Andrew R. Ferguson, Karin Jooss - Nature Medicine 2024 cited by 127

  6. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer

    Authors: Scott Kopetz, Jayesh Desai, Emily Chan, J. Randolph Hecht, Peter J. O’Dwyer, Dipen M. Maru, Van K. Morris, Filip Jankú, Arvind Dasari, Woonbok Chung, Jean‐Pierre J. Issa, Peter Gibbs, Brian P. James, Garth Powis, K. B. Nolop, Suman Bhattacharya, Leonard B. Saltz - Journal of Clinical Oncology 2015 cited by 693

  7. A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First-Line Treatment of Pancreatic Adenocarcinoma

    Authors: Al B. Benson, Zev A. Wainberg, J. Randolph Hecht, Dmitry Vyushkov, Hua Dong, Johanna C. Bendell, Fred J. Kudrik - The Oncologist 2017 cited by 176

  8. Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology

    Authors: Al B. Benson, Alan P. Venook, Mohamed A. Adam, George J. Chang, Yi-Jen Chen, Kristen K. Ciombor, Stacey A. Cohen, Harry S. Cooper, Dustin A. Deming, Ignacio Garrido‐Laguna, Jean L. Grem, Paul Haste, J. Randolph Hecht, Sarah E. Hoffe, Steven R. Hunt, Hisham Hussan, Kimberly L. Johung, Nora Joseph, Natalie Kirilcuk, Smitha Krishnamurthi, Midhun Malla, Jennifer K. Maratt, Wells A. Messersmith, Jeffrey A. Meyerhardt, Eric D. Miller, Mary F. Mulcahy, Steven Nurkin, Michael J. Overman, Aparna Parikh, Hitendra Patel, Katrina S. Pedersen, Leonard B. Saltz, Charles Schneider, David Shibata, Benjamin D. Shogan, John M. Skibber, Constantinos T. Sofocleous, Anna Tavakkoli, Christopher G. Willett, Christina Wu, Lisa A. Gurski, Jenna Snedeker, Frankie Jones - Journal of the National Comprehensive Cancer Network 2024 cited by 308

  9. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC—A Randomized Phase III Trial

    Authors: J. Randolph Hecht, Yung‐Jue Bang, Shukui Qin, Hyun Cheol Chung, Jianming Xu, Joon Oh Park, Krzysztof Jeziorski, Yaroslav Shparyk, Paulo M. Hoff, Alberto Sobrero, Pamela Salman, Jin Li, Светлана Проценко, Zev A. Wainberg, Marc Buyse, Karen Afenjar, Vincent Houé, Agathe Garcia, Tomomi Kaneko, Yingjie Huang, S. Khan‐Wasti, Sergio Santillana, Michael F. Press, Dennis J. Slamon - Journal of Clinical Oncology 2015 cited by 621

  10. A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab in Combination with FOLFIRI for the Second-Line Treatment of Metastatic KRAS Mutant Colorectal Adenocarcinoma

    Authors: J. Randolph Hecht, Al B. Benson, Dmitry Vyushkov, Yingsi Yang, Johanna C. Bendell, Udit Verma - The Oncologist 2017 cited by 126

  11. NCCN Guidelines® Insights: Rectal Cancer, Version 3.2024

    Authors: Al B. Benson, Alan P. Venook, Mohamed A. Adam, George J. Chang, Yi-Jen Chen, Kristen K. Ciombor, Stacey A. Cohen, Harry S. Cooper, Dustin A. Deming, Ignacio Garrido‐Laguna, Jean L. Grem, Paul Haste, J. Randolph Hecht, Sarah E. Hoffe, Steven R. Hunt, Hisham Hussan, Kimberly L. Johung, Nora Joseph, Natalie Kirilcuk, Smitha Krishnamurthi, Midhun Malla, Jennifer K. Maratt, Wells A. Messersmith, Jeffrey A. Meyerhardt, Eric D. Miller, Mary F. Mulcahy, Steven Nurkin, Aparna Parikh, Hitendra Patel, Katrina S. Pedersen, Leonard B. Saltz, Charles Schneider, David Shibata, Benjamin D. Shogan, John M. Skibber, Constantinos T. Sofocleous, Anna Tavakkoli, Christopher G. Willett, Christina Wu, Frankie Jones, Lisa A. Gurski - Journal of the National Comprehensive Cancer Network 2024 cited by 215

  12. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial

    Authors: Aimery de Gramont, Eric Van Cutsem, Hans‐Joachim Schmoll, Josep Tabernero, Stephen Clarke, Malcolm J. Moore, David Cunningham, Thomas H. Cartwright, J. Randolph Hecht, Fernando Rivera, Seock‐Ah Im, G. Bodoky, Ramón Salazar, Frédérique Maindrault-Goebel, Einat Shacham‐Shmueli, Emilio Bajetta, Martina Makrutzki, Aijing Shang, Thierry André, Paulo M. Hoff - The Lancet Oncology 2012 cited by 526

  13. Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)

    Authors: J. Randolph Hecht, Sara Lonardi, Johanna C. Bendell, Hao‐Wen Sim, Teresa Macarulla, Charles D. Lopez, Eric Van Cutsem, Andrés J. Muñoz Martín, Joon Oh Park, Richard Greil, Hong Wang, Rebecca R. Hozak, Ivelina Gueorguieva, Yong Lin, Sujata Rao, Baek‐Yeol Ryoo - Journal of Clinical Oncology 2021 cited by 110

  14. Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases

    Authors: J. Randolph Hecht, Steven S. Raman, Arlene Chan, Kevin Kalinsky, Jean‐François Baurain, M.M. Jimenez, Maria Martinez‐García, Martin D. Berger, Ulrich M. Lauer, A. Khattak, Alfredo Carrato, Yue Zhang, K. Liu, Edward Cha, Alissa Keegan, Sumita Bhatta, C.P. Strassburg, Aflah Roohullah - ESMO Open 2023 cited by 39

  15. Safety, efficacy, and on-treatment circulating tumor DNA (ctDNA) changes from a phase 1 study of RMC-6236, a RAS(ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC).

    Authors: Ignacio Garrido‐Laguna, Brian M. Wolpin, Wungki Park, Nilofer S. Azad, Alexander I. Spira, Alexander Starodub, David Sommerhalder, Salman R. Punekar, Benjamin Herzberg, Minal Barve, Meredith S. Pelster, Jennifer Brooke Valerin, J. Randolph Hecht, Rashmi Vora, Aparna Hegde, Clay Gustafson, Tao Lin, Sumit Kar, Kevin Lin, David S. Hong - Journal of Clinical Oncology 2025 cited by 39

  16. A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer

    Authors: J. Randolph Hecht, Edith P. Mitchell, Tarek Chidiac, Carroll Scroggin, Christopher Hagenstad, David R. Spigel, John L. Marshall, Allen Lee Cohn, David McCollum, Philip J. Stella, Robert G Deeter, Seta Shahin, Rafael G. Amado - Journal of Clinical Oncology 2008 cited by 852

  17. Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer

    Authors: Efrat Dotan, Steven J. Cohen, Alexander Starodub, Christopher H. Lieu, Wells A. Messersmith, Pamela S. Simpson, Michael J. Guarino, John L. Marshall, Richard M. Goldberg, J. Randolph Hecht, William A. Wegener, Robert M. Sharkey, Serengulam V. Govindan, David M. Goldenberg, Jordan Berlin - Journal of Clinical Oncology 2017 cited by 118

  18. A phase Ib/II study of the anti-CD47 antibody magrolimab with cetuximab in solid tumor and colorectal cancer patients.

    Authors: George A. Fisher, Nehal J. Lakhani, Cathy Eng, J. Randolph Hecht, Johanna C. Bendell, Philip Agop Philip, Peter J. O’Dwyer, Benny Johnson, Adel Kardosh, Tina M Ippolito, Yan V. Wang, Balaji Agoram, Jens-Peter Volkmer, Roy L. Maute, Isagani Chico, Mark P. Chao, Chris H. Takimoto, Amita Patnaik - Journal of Clinical Oncology 2020 cited by 53

  19. Addition of Bevacizumab to Bolus Fluorouracil and Leucovorin in First-Line Metastatic Colorectal Cancer: Results of a Randomized Phase II Trial

    Authors: Fairooz F. Kabbinavar, Joseph J. Schulz, Michael McCleod, Taral Patel, John Hamm, J. Randolph Hecht, R. Mass, B. Perrou, B. Nelson, William Novotny - Journal of Clinical Oncology 2005 cited by 933

  20. PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer

    Authors: Lee S. Schwartzberg, Fernando Rivera, Meinolf Karthaus, Gianpiero Fasola, Jean-Luc Canon, J. Randolph Hecht, Hua Yu, Kelly S. Oliner, William Y. Go - Journal of Clinical Oncology 2014 cited by 632

  21. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma.

    Authors: J. Randolph Hecht, Rudolph A. Bedford, James L. Abbruzzese, Sandeep Lahoti, Tony R. Reid, Roy Soetikno, David H. Kirn, Sara M. Freeman - 2003 cited by 496

  22. Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project

    Authors: Katrin Marie Sjoquist, Lindsay A. Renfro, R. John Simes, Niall C. Tebbutt, Stephen Clarke, Michel Seymour, Richard Adams, Tim Maughan, Leonard B. Saltz, Richard M. Goldberg, Hans‐Joachim Schmoll, Eric Van Cutsem, Jean‐Yves Douillard, Paulo M. Hoff, J. Randolph Hecht, Christophe Tournigand, Cornelis J.A. Punt, Miriam Koopman, Herbert I. Hurwitz, Volker Heinemann, Alfredo Falcone, Rainer Porschen, Charles S. Fuchs, Eduardo Díaz‐Rubio, Enrique Aranda, Carsten Bokemeyer, Ioannis Souglakos, Fairooz F. Kabbinavar, Benoist Chibaudel, Jeffrey P. Meyers, Daniel J. Sargent, Aimery de Gramont, John Zalcberg, The Fondation Aide et Recherche en Cancerologie Digestive Group (ARCAD) - JNCI Journal of the National Cancer Institute 2017 cited by 144

  23. Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

    Authors: Charles D. Blanke, Cathryn Rankin, George D. Demetri, Christopher W. Ryan, Margaret von Mehren, Robert S. Benjamin, A. Kevin Raymond, Vivien Bramwell, Laurence H. Baker, Robert G. Maki, Michael Tanaka, J. Randolph Hecht, Michael C. Heinrich, Christopher D.�M. Fletcher, John J. Crowley, Ernest C. Borden - Journal of Clinical Oncology 2008 cited by 1,077

  24. Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer

    Authors: Michael P. Chu, J. Randolph Hecht, Dennis J. Slamon, Zev A. Wainberg, Yung‐Jue Bang, Paulo M. Hoff, Alberto F. Sobrero, Shukui Qin, Karen Afenjar, Vincent Houé, Karen L. King, Sheryl Koski, Karen Mulder, Julie Price Hiller, Andrew Scarfe, Jennifer L. Spratlin, Yingjie Huang, S. Khan‐Wasti, Neil Chua, Michael B. Sawyer - JAMA Oncology 2016 cited by 106